Clinical Trial Update: Special Drug Use-results Surveillance of Tabrecta Tablets

View source ↗

Summary

The document reports results from Special Drug Use surveillance of Tabrecta (capmatinib) tablets in non-small cell lung cancer, with the study NCT04575025 spons…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tabrecta (Capmatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Status: COMPLETED